C L Thors1, J A Broeckel, P B Jacobsen. 1. Psychosocial and Palliative Care Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Abstract
BACKGROUND: A growing body of evidence suggests that sexual dysfunction may be among the more common and distressing symptoms experienced by breast cancer survivors. METHODS: This report reviews studies in which sexual functioning in breast cancer survivors has been investigated. Included are reports on the prevalence and nature of sexual difficulties, the relationship between specific breast cancer treatments and sexual difficulties, and the treatment of sexual dysfunction following completion of breast cancer treatment. RESULTS: A review of the literature suggests a wide range of rates for the prevalence of sexual problems in breast cancer survivors. Factors that may affect prevalence rates include the methods used to determine prevalence and the demographic and medical characteristics of the patients studied. With regard to treatment effects, evidence suggests that breast cancer patients who undergo chemotherapy are at high risk for sexual dysfunction after treatment. In contrast, there is little evidence of a link between type of surgical treatment (eg, lumpectomy vs mastectomy) or treatment with tamoxifen and sexual functioning outcomes. CONCLUSIONS: A growing body of evidence suggests that sexual problems can be a long-term side effect of breast cancer treatment. Oncology professionals should initiate communication about sexual difficulties, perform comprehensive assessments, and educate and counsel patients about the management of these difficulties.
BACKGROUND: A growing body of evidence suggests that sexual dysfunction may be among the more common and distressing symptoms experienced by breast cancer survivors. METHODS: This report reviews studies in which sexual functioning in breast cancer survivors has been investigated. Included are reports on the prevalence and nature of sexual difficulties, the relationship between specific breast cancer treatments and sexual difficulties, and the treatment of sexual dysfunction following completion of breast cancer treatment. RESULTS: A review of the literature suggests a wide range of rates for the prevalence of sexual problems in breast cancer survivors. Factors that may affect prevalence rates include the methods used to determine prevalence and the demographic and medical characteristics of the patients studied. With regard to treatment effects, evidence suggests that breast cancerpatients who undergo chemotherapy are at high risk for sexual dysfunction after treatment. In contrast, there is little evidence of a link between type of surgical treatment (eg, lumpectomy vs mastectomy) or treatment with tamoxifen and sexual functioning outcomes. CONCLUSIONS: A growing body of evidence suggests that sexual problems can be a long-term side effect of breast cancer treatment. Oncology professionals should initiate communication about sexual difficulties, perform comprehensive assessments, and educate and counsel patients about the management of these difficulties.
Authors: L V van de Poll-Franse; F Mols; A J J M Vingerhoets; A C Voogd; R M H Roumen; J W W Coebergh Journal: Support Care Cancer Date: 2006-01-10 Impact factor: 3.603
Authors: Katharine Hodgkinson; Phyllis Butow; Glenn E Hunt; Susan Pendlebury; Kim M Hobbs; Gerard Wain Journal: Support Care Cancer Date: 2006-11-21 Impact factor: 3.603
Authors: Kathryn E Flynn; Jennifer Barsky Reese; Diana D Jeffery; Amy P Abernethy; Li Lin; Rebecca A Shelby; Laura S Porter; Carrie B Dombeck; Kevin P Weinfurt Journal: Psychooncology Date: 2011-03-10 Impact factor: 3.894
Authors: Kathryn M Greven; L Douglas Case; Lawrence R Nycum; Patricia J Zekan; David D Hurd; Ernie P Balcueva; Glenn M Mills; Robin Zon; Patrick J Flynn; David Biggs; Edward G Shaw; Glenn Lesser; Michelle J Naughton Journal: J Community Support Oncol Date: 2015-03
Authors: Alfred C Marcus; Kathleen M Garrett; David Cella; Lari Wenzel; Marianne J Brady; Diane Fairclough; Meredith Pate-Willig; Denise Barnes; Susan Powell Emsbo; Brenda C Kluhsman; Lori Crane; Scot Sedlacek; Patrick J Flynn Journal: Psychooncology Date: 2010-09 Impact factor: 3.894